Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK | Market Cap | 1.03B +36.7% |
| Revenue (ttm) | 4.60M -94.1% |
| Net Income | -227.37M |
| EPS | -0.72 |
| Shares Out | 326.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.00 (31.75%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 863,731 |
| Open | 3.125 |
| Previous Close | 3.215 |
| Day's Range | 3.120 - 3.210 |
| 52-Week Range | 2.058 - 5.200 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 6.25 (+98.41%) |
| Earnings Date | Nov 25, 2026 |
About Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with ... [Read more]
Financial Performance
In 2025, Nykode Therapeutics AS's revenue was $453,000, a decrease of -95.05% compared to the previous year's $9.16 million. Losses were -$12.24 million, -68.47% less than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NYKD stock is "Strong Buy." The 12-month stock price target is kr 6.25, which is an increase of 98.41% from the latest price.
News
Nykode Therapeutics AS Slides: H.C. Wainwright 28th Annual Global Investment Conference presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on September 16, 2026.
Nykode Therapeutics AS Earnings Call Transcript: Q2 2026
Lead oncology and neoantigen assets are advancing, with the Abili-T phase II trial on track for interim results in 2027 and VB10.NEO showing strong clinical and manufacturing progress. Financials show a net loss and robust cash position, with a pending tax case potentially extending runway.
Nykode Therapeutics AS Quarterly report: Q2 2026
Nykode Therapeutics AS has published its Q2 2026 quarterly earnings report on August 26, 2026.
Nykode Therapeutics AS Slides: Q2 2026
Nykode Therapeutics AS has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 26, 2026.
Nykode Therapeutics AS Slides: Company presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on August 26, 2026.
Nykode Therapeutics AS Slides: Investor presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on July 22, 2026.
Nykode Therapeutics AS Earnings Call Transcript: Q1 2026
Abi-suva advanced to phase II with strong interim efficacy data, while cash reserves support operations into 2028. Autoimmune and neoantigen platforms progress, with AI integral to R&D and a key tax case outcome pending by September.
Nykode Therapeutics AS Quarterly report: Q1 2026
Nykode Therapeutics AS has published its Q1 2026 quarterly earnings report on May 27, 2026.
Nykode Therapeutics AS Slides: Q1 2026
Nykode Therapeutics AS has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 27, 2026.
Nykode Therapeutics AS Slides: Company presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Nykode Therapeutics AS Slides: 25th BioPharma Drug Discovery presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on April 29, 2026.
Nykode Therapeutics AS Slides: Development of APC-targeted antigen-apecific immune tolerance therapies for autoimmune diseases presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Nykode Therapeutics AS Slides: VB10.NEO presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Nykode Therapeutics AS Slides: FY 2026
Nykode Therapeutics AS has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 20, 2026.
Nykode Therapeutics AS Slides: DNB Carnegie Nordic Healthcare Conference presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Nykode Therapeutics AS Slides: FY 2026
Nykode Therapeutics AS has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 5, 2026.
Nykode Therapeutics AS Earnings Call Transcript: Q4 2025
Q4 2025 saw strong clinical progress, notably with abisuvva's superior response rates in head and neck cancer and new patents for the VB10.NEO platform. Operating expenses fell sharply, with a solid cash runway into 2028 and key trial milestones expected in 2026-2027.
Nykode Therapeutics AS Quarterly report: Q4 2025
Nykode Therapeutics AS has published its Q4 2025 quarterly earnings report on February 25, 2026.
Nykode Therapeutics AS Slides: Q4 2025
Nykode Therapeutics AS has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Nykode Therapeutics AS Annual report: Q4 2025
Nykode Therapeutics AS has published its Q4 2025 annual report on February 25, 2026.
Nykode Therapeutics AS Slides: Investor presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on February 25, 2026.
Nykode Therapeutics AS Slides: Company presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.
Nykode Therapeutics AS Slides: DNB Carnegie Nordic Healthcare Conference presentation
Nykode Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on November 25, 2025.
Nykode Therapeutics AS Earnings Call Transcript: Q3 2025
Advanced lead cancer immunotherapy into phase II, secured new patents for neoantigen platform, and demonstrated strong preclinical results for autoimmune tolerance. Reduced operating expenses and maintained a strong cash position, with a runway into 2028 and key data readouts expected in 2026–2027.
Nykode Therapeutics AS Quarterly report: Q3 2025
Nykode Therapeutics AS has published its Q3 2025 quarterly earnings report on November 24, 2025.